S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
66,000% upside on tiny biotech? (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
⚡ 2,467% Return on Israeli Laser Company? (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
66,000% upside on tiny biotech? (Ad)
Stock market today: Asian stocks rise after Wall St retreats on concern economy weakening
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
66,000% upside on tiny biotech? (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
⚡ 2,467% Return on Israeli Laser Company? (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
66,000% upside on tiny biotech? (Ad)
Stock market today: Asian stocks rise after Wall St retreats on concern economy weakening
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
66,000% upside on tiny biotech? (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
⚡ 2,467% Return on Israeli Laser Company? (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
66,000% upside on tiny biotech? (Ad)
Stock market today: Asian stocks rise after Wall St retreats on concern economy weakening
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
66,000% upside on tiny biotech? (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
⚡ 2,467% Return on Israeli Laser Company? (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
66,000% upside on tiny biotech? (Ad)
Stock market today: Asian stocks rise after Wall St retreats on concern economy weakening
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
NASDAQ:RGNX

REGENXBIO (RGNX) Stock Forecast, Price & News

$19.22
-0.50 (-2.54%)
(As of 06/5/2023 ET)
Compare
Today's Range
$19.17
$20.23
50-Day Range
$17.23
$21.71
52-Week Range
$17.02
$35.73
Volume
331,002 shs
Average Volume
416,175 shs
Market Capitalization
$835.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$40.25

REGENXBIO MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
109.4% Upside
$40.25 Price Target
Short Interest
Bearish
12.32% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.82
Upright™ Environmental Score
News Sentiment
0.58mentions of REGENXBIO in the last 14 days
Based on 11 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.31) to ($2.46) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.04 out of 5 stars

Medical Sector

477th out of 986 stocks

Biological Products, Except Diagnostic Industry

79th out of 166 stocks


RGNX stock logo

About REGENXBIO (NASDAQ:RGNX) Stock

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Receive RGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for REGENXBIO and its competitors with MarketBeat's FREE daily newsletter.

RGNX Stock News Headlines

Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
REGENXBIO (NASDAQ:RGNX) Shares Down 7.5%
StockNews.com Initiates Coverage on REGENXBIO (NASDAQ:RGNX)
REGENXBIO (NASDAQ:RGNX) Shares Up 8.8%
Analyst Expectations for Regenxbio's Future
REGENXBIO (NASDAQ:RGNX) PT Lowered to $55.00
See More Headlines

RGNX Price History

RGNX Company Calendar

Last Earnings
5/03/2023
Today
6/05/2023
Next Earnings (Estimated)
8/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RGNX
Fax
N/A
Employees
372
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$40.25
High Stock Price Forecast
$61.00
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+104.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

Net Income
$-280,320,000.00
Net Margins
-246.50%
Pretax Margin
-246.54%

Debt

Sales & Book Value

Annual Sales
$112.72 million
Book Value
$11.92 per share

Miscellaneous

Free Float
37,555,000
Market Cap
$853.75 million
Optionable
Optionable
Beta
1.04

Key Executives

  • Kenneth T. MillsKenneth T. Mills
    President, Chief Executive Officer & Director
  • Curran M. Simpson
    Chief Operating Officer
  • Vit Vasista
    Chief Financial Officer & Senior Vice President
  • Jerome W. Jackson
    Vice President-Information Technology
  • Olivier Danos
    Chief Scientific Officer & Senior Vice President













RGNX Stock - Frequently Asked Questions

Should I buy or sell REGENXBIO stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for REGENXBIO in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RGNX shares.
View RGNX analyst ratings
or view top-rated stocks.

What is REGENXBIO's stock price forecast for 2023?

7 Wall Street research analysts have issued 12-month price targets for REGENXBIO's stock. Their RGNX share price forecasts range from $14.00 to $61.00. On average, they anticipate the company's stock price to reach $40.25 in the next twelve months. This suggests a possible upside of 104.9% from the stock's current price.
View analysts price targets for RGNX
or view top-rated stocks among Wall Street analysts.

How have RGNX shares performed in 2023?

REGENXBIO's stock was trading at $22.68 on January 1st, 2023. Since then, RGNX shares have decreased by 13.4% and is now trading at $19.64.
View the best growth stocks for 2023 here
.

When is REGENXBIO's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our RGNX earnings forecast
.

How were REGENXBIO's earnings last quarter?

REGENXBIO Inc. (NASDAQ:RGNX) posted its earnings results on Wednesday, May, 3rd. The biotechnology company reported ($1.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.52) by $0.01. The biotechnology company had revenue of $19.10 million for the quarter, compared to analyst estimates of $31.29 million. REGENXBIO had a negative net margin of 246.50% and a negative trailing twelve-month return on equity of 49.69%. The firm's revenue for the quarter was down 14.0% on a year-over-year basis. During the same quarter last year, the company earned ($1.62) EPS.

What is Ken Mills' approval rating as REGENXBIO's CEO?

3 employees have rated REGENXBIO Chief Executive Officer Ken Mills on Glassdoor.com. Ken Mills has an approval rating of 68% among the company's employees.

What other stocks do shareholders of REGENXBIO own?

Based on aggregate information from My MarketBeat watchlists, some companies that other REGENXBIO investors own include AbbVie (ABBV), Micron Technology (MU), NVIDIA (NVDA), Voyager Therapeutics (VYGR), Amarin (AMRN), CRISPR Therapeutics (CRSP), Pfizer (PFE), QUALCOMM (QCOM), Gilead Sciences (GILD) and Block (SQ).

What is REGENXBIO's stock symbol?

REGENXBIO trades on the NASDAQ under the ticker symbol "RGNX."

Who are REGENXBIO's major shareholders?

REGENXBIO's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (18.50%), JPMorgan Chase & Co. (9.21%), State Street Corp (5.94%), Dimensional Fund Advisors LP (3.53%), Geode Capital Management LLC (1.75%) and First Manhattan CO. LLC. (1.03%). Insiders that own company stock include Allan M Fox, Curran Simpson, Kenneth T Mills, Kenneth T Mills, Patrick J Christmas, Steve Pakola, Vittal Vasista and WR Stephens, Iii 2012 Trust.
View institutional ownership trends
.

How do I buy shares of REGENXBIO?

Shares of RGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is REGENXBIO's stock price today?

One share of RGNX stock can currently be purchased for approximately $19.64.

How much money does REGENXBIO make?

REGENXBIO (NASDAQ:RGNX) has a market capitalization of $853.75 million and generates $112.72 million in revenue each year. The biotechnology company earns $-280,320,000.00 in net income (profit) each year or ($6.24) on an earnings per share basis.

How many employees does REGENXBIO have?

The company employs 372 workers across the globe.

How can I contact REGENXBIO?

REGENXBIO's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The official website for the company is www.regenxbio.com. The biotechnology company can be reached via phone at (240) 552-8181 or via email at ir@regenxbio.com.

This page (NASDAQ:RGNX) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -